Mechanisms of Anxiety and Depression Study
Transdiagnostic Endophenotypes of Anxiety and Depression
1 other identifier
observational
63
1 country
2
Brief Summary
Eligible participants will come in for three separate visits in which they will be interviewed, perform a variety of tasks, and undergo a non-invasive MRI scan. The investigators anticipate that (1) participants with anxiety and depression will likely perform differently than the healthy controls on cognitive tasks, (2) participants with anxiety and depression will likely show differences in brain functionality compared to the healthy controls, and (3) depression and anxiety likely share some underlying mechanisms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Mar 2015
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 19, 2015
CompletedFirst Submitted
Initial submission to the registry
April 21, 2017
CompletedFirst Posted
Study publicly available on registry
May 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 14, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
March 14, 2018
CompletedMay 11, 2018
May 1, 2018
3 years
April 21, 2017
May 9, 2018
Conditions
Outcome Measures
Primary Outcomes (3)
Brain imaging
Non-invasive MRI brain scan to see function and structure of brain
Day 1
Assessment of symptoms and daily functioning
Structured Clinical Interview for DSM-IV, General demographic questionnaires, Penn State Worry Questionnaire, Intolerance of Uncertainty Questionnaire, The Positive and Negative Affect Schedule, Behavioral Inhibition Scale/Behavioral Activation Scale, The NEO Five-Factor Inventory, Mood and Anxiety Symptom Questionnaire, Alcohol Use Disorders Identification Test, Behavioral Regulation Index and Metacognition Index, General temperament Survey, Questionnaire of Mental Imagery, Rumination Reflection Questionnaire, Drug Abuse Screening Test, Childhood Trauma Questionnaire- Factor Structure, Emotion Regulation Questionnaire, Trait Meta-Mood Scale
Day 1
Cognitive assessment
Objective assessment of cognitive strengths and weaknesses via neuropsychological testing session
Day 1
Study Arms (2)
Depression and anxiety symptoms
Healthy controls
Eligibility Criteria
The investigators expect to enroll 50 right-handed, English as first language, adults will be recruited from the community through various advertisements. The investigators expect that 25 will be healthy controls and 25 will be a clinical sample exhibiting clinically significant symptoms of anxiety and depression.
You may qualify if:
- Right-handed
- Healthy with no medical conditions OR have a history of anxiety and/or depression
- Ability to travel to both Palo Alto University and Stanford University
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Palo Alto University
Los Altos, California, 94022, United States
Stanford University
Stanford, California, 94035, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stacie Warren, PhD
Palo Alto University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Primary Investigator
Study Record Dates
First Submitted
April 21, 2017
First Posted
May 1, 2017
Study Start
March 19, 2015
Primary Completion
March 14, 2018
Study Completion
March 14, 2018
Last Updated
May 11, 2018
Record last verified: 2018-05